Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2018
Price : $35 *
At a glance
- Drugs WASp gene therapy (Primary)
- Indications Wiskott-Aldrich syndrome
- Focus First in man; Therapeutic Use
- Sponsors Genethon
- 21 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 21 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 21 May 2018 Status changed to recruiting.